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Abstract
Background: Influenza B is one of the major etiologies for acute respiratory infec-
tions (ARI) among children worldwide; however, its clinical- epidemiological informa-
tion is limited. We aimed to investigate the hospitalization incidence and 
clinical- epidemiological characteristics of influenza B- associated paediatric ARIs in 
central Vietnam.
Methods: We collected clinical- epidemiological information and nasopharyngeal 
swabs from ARI children hospitalized at Khanh Hoa General Hospital, Nha Trang, 
Vietnam from February 2007 through June 2013. Nasopharyngeal samples were 
screened for 13 respiratory viruses using Multiplex- PCRs. Influenza B- confirmed 
cases were genotyped by Haemagglutinin gene sequencing. We analyzed the clinical- 
epidemiological characteristics of influenza B Lineages (Victoria/Yamagata) and 
WHO Groups.
Results: In the pre- A/H1N1pdm09 period, influenza B- associated ARI hospitalization 
incidence among children under five was low, ranging between 14.7 and 80.7 per 
100 000 population. The incidence increased to between 51.4 and 330 in the post-
 A/H1N1pdm09. Influenza B ARI cases were slightly older with milder symptoms. 
Both Victoria and Yamagata lineages were detected before the A/H1N1pdm09 out-
break; however, Victoria lineage became predominant in 2010- 2013 (84% Victoria vs 
16% Yamagata). Victoria and Yamagata lineages did not differ in demographic and 
clinical characteristics. In Victoria lineage, Group1 ARI cases were clinically more se-
vere compared to Group5, presenting a greater proportion of wheeze, tachypnea, 
and lower respiratory tract infection.
Conclusions: The current results highlight the increased incidence of influenza B- 
related ARI hospitalization among children in central Vietnam in the post- A/
H1N1pdm09 era. Furthermore, the difference in clinical severity between Victoria 
lineage Group1 and 5 implies the importance of influenza B genetic variation on clini-
cal presentation.
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1  | INTRODUC TION
Influenza viruses belong to the family Orthomyxoviridae, which 
possess a segmented negative- stranded RNA genome.1,2 Among 
three influenza types, namely, type- A, B and C, influenza A and 
B often cause seasonal acute respiratory infections (ARI) epi-
demics and impose a high socioeconomic burden, particularly 
among children and the elderly population.3,4 In temperate cli-
mate regions, peaks of influenza- associated ARIs may appear in 
early autumn through winter,5 whereas year- round circulation 
with no apparent seasonal trend may be seen in tropical climate 
regions.6-9
Influenza B differs from type- A in terms of genetic composi-
tion and its ability to infect only humans and seals.10,11 Two surface 
glycoproteins, Haemagglutinin (HA) and Neuraminidase (NA), play 
pivotal roles during pathogenesis.12 Unlike influenza A, influenza B 
does not possess multiple subtypes. Instead, influenza B obtains its 
genetic variation mainly through genetic drift, including nucleotide 
substitutions, insertions, and deletions, which explains the slower 
molecular evolutionary rate and smaller capacity to cause seasonal 
ARI outbreaks compared to influenza A.13,14 Genetic reassortment 
of influenza B genetic components was previously documented15; 
however, its frequency is not as high as that of influenza A due to its 
limited animal reservoir.
Despite the clinical importance of influenza B among ARI cases, 
majority of previous literature focused on influenza A. Therefore, 
clinical and molecular epidemiological information on influenza B is 
relatively limited worldwide.
The first influenza B strain B/Lee/40 was isolated in 1940.16 
In the 1970s, influenza B diverged into two genetically and anti-
genically distinct lineages, Victoria- like (B/Victoria/2/87) and 
Yamagata- like (B/Yamagata/16/88) lineages.17,18 Since then, the 
two lineages have been co- circulating in many regions of the 
world.19 Previous studies from Cambodia, China, India, and Taiwan 
have reported the increase of influenza B- associated ARI cases 
in the following seasons after the emergence of the pandemic A/
H1N1pdm09 strain.4,17,18,20,21 Furthermore, some studies pre-
sented the circulation of Victoria lineage as a dominant type in the 
post- A/H1N1pdm09 period,17,18,20-23 whereas others showed co- 
circulation of both lineages.3,4 Regardless of a few epidemiological 
studies on influenza B lineage- specific clinical presentation,21,23 
the clinical aspect of two genetically distinct lineages has not been 
clearly understood up to date.
In this study, we investigated the incidence and clinical- 
epidemiological characteristics of paediatric hospitalized influenza 
B ARI cases in Vietnam.
2  | METHODS
2.1 | Study site, period, and case enrollment
Population- based prospective paediatric ARI surveillance in Khanh 
Hoa province, Nha Trang, Vietnam was established in February 
2007.24 All children from 16 communes admitted to the paediat-
ric ward of Khanh Hoa General Hospital (KHGH), which is the only 
hospital in the region, due to ARI symptoms (cough and/or difficulty 
breathing) from February 2007 to June 2013 were enrolled in the 
current study. Nha Trang city in south central region of Vietnam has 
a hot and dry season or tropical climate with a short rainy or wet 
season from September to December. The detailed characteriza-
tion of the target population was described in the previous study.24 
Written informed consent from the parents or guardians of all the 
enrolled ARI children were obtained. Nasopharyngeal (NP) swab, 
clinical- epidemiological information, chest radiograph, and labora-
tory test data were collected from each enrollee. Currently, vaccina-
tion against influenza type A and B is not included in the nationwide 
immunization program in Vietnam. Its availability in our study site is 
limited and not commonly used among children.
2.2 | Clinical information categorization
Lower respiratory tract infection (LRTI) was defined based on the 
modified World Health Organization (WHO) Integrated Management 
of Childhood Illnesses (IMCI) algorithms.25 The presence of tachyp-
nea (respiratory rate >60/min for children ≦1 month, >50/min for 
2- 11 months and >40/min for 12- 59 months of age) was categorized 
as mild LRTIs. Furthermore, children with a general danger sign (the 
situation in which children were either unable to drink, under convul-
sion, or lethargy), chest- wall indrawing, or stridor were categorized 
as severe LRTIs. Radiologically- confirmed pneumonia was defined 
as the presence of either substantial alveolar consolidation or pleu-
ral effusion in chest X- ray result following the standardized inter-
pretation method established by WHO Vaccine Trial Investigators 
Group.26 ARI cases with abnormal shadow but neither substantial al-
veolar consolidation nor pleural effusion were categorized into chest 
X- ray abnormality or other lower respiratory infections.26
2.3 | Viral screening and influenza B sequencing
Viral nucleic acids were extracted from ARI patient’s NP swabs using 
QIA Viral RNA Minikit (QIAGEN Inc., Valencia, CA, USA) following 
the company’s instructions. Four multiplex Reverse Transcriptase 
(RT)- PCR assays were performed for screening 13 respiratory vi-
ruses, including RSV, influenza A and B, Human Metapneumovirus, 
K E Y W O R D S
acute respiratory infections, influenza B, molecular epidemiology, paediatric infectious 
diseases, Vietnam

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































     |  251YOSHIHARA et Al.
Parainfluenza virus 1- 4, Human Coronavirus (229E and OC43), 
Adenovirus, and Bocavirus as previously described.24 For the cur-
rent study, the presence of bacterial pathogens in the clinical sam-
ples was not tested.
Influenza B- confirmed ARI samples were genotyped by 
Haemagglutinin (HA) gene sequencing using BigDye Terminator 
ver.3.1 cycle sequencing kit (Applied Biosystem, Foster City, CA, 
USA) with 3730 DNA Analyzer (Applied Biosystem, Foster City, 
CA, USA). Influenza B reference sequences including WHO recom-
mended vaccine strains for northern hemisphere from 2007 to 2014 
(https://www.who.int/influenza/vaccines/virus/recommendations/
en/) were obtained from GenBank (http://www.ncbi.nlm.nih.gov/
genbank/) and EpiFlu database within Global Initiative on Sharing 
All Influenza Data (GISAID)(http://platform.gisaid.org) and included 
in phylogenetic analysis as previously described.17,23,27 These refer-
ence strains were used in order to further classify lineage into groups 
based on Worldwide Influenza Centre (WIC) (https://www.crick.
ac.uk/partnerships/worldwide-influenza-centre). Multiple nucleo-
tide sequences of HA gene were aligned and edited with ClustalW 
algorism implemented within BioEdit ver.7.2.0. KAKUSAN4 (http://
www.fifthdimension.jp/products/kakusan/) was used for the selec-
tion of best- fit nucleotide substitution model.28 Phylogenetic analy-
ses were performed with Maximum- Likelihood (ML) method under 
HKY- 85 substitution model (gamma- distribution) with bootstrap 
value of 1000 replicates using MEGA ver.6.0.6.29
2.4 | Statistical analysis
Either two- tailed Pearson’s chi- squared or Fisher’s exact test was 
performed to compare the proportions between independent groups. 
For continuous variables, either Mann–Whitney U test or Kruskal–
Wallis test were utilized to compare the median values between in-
dependent groups. In the multivariate analysis, Generalized Linear 
Model with log- binomial regression was applied to estimate adjusted 
Relative Risk (Adj RR) and 95% Confidence Interval (CI). To control 
demographic confounding variables in the multivariate regression 
analysis, both forward- selection step and biologically plausible ap-
proaches were taken into account. For the estimation of potential 
impact of A/H1N1pdm09 emergence on influenza B- associated ARI 
hospitalization incidence among Vietnamese children, we utilized the 
Generalized Linear Model (GLM) with Poisson distribution.30 The fol-
lowing equation was used as a standard regression model:
1. Yt: the number of influenza B-associated ARI hospitalization 
cases at time (t)
2. T: the time (in month-interval) elapsed since the beginning of pae-
diatric ARI surveillance in central Vietnam (February, 2007)
3. Xt: the variable for “Pre-A/H1N1pdm09” (February 2007-March 
2010)(coded as 0) and “Post-A/H1N1pdm09” (April 2010-June 
2013)(coded as 1)
where the function of f (t) adjusts for short- term seasonal trend 
using the Fourier term (pairs of sine- cosine functions) with four har-
monic terms (2 sine- cosine pairs). The values of Akaike Information 
Criterion (AIC) in the models with different numbers of harmonic 
terms [up to 12 (6 sine- cosine pairs)] were compared in order to de-
termine the best- fit harmonic terms in the final model.31 The “Post- A/
H1N1pdm09” was defined as (April 2010- June 2013), based on the 
AIC comparison in 12 different models (1 month interval), in which 
“Post- A/H1N1pdm09” was defined at different time points, starting 
from January 2010 to December 2010. All the statistical analyses 
were performed using STATA ver.14.1 (StataCorp LP, College Station, 
TX, USA). P- values less than 0.05 were considered to be statistically 
significant.
2.5 | Ethics
This study was approved by the institutional ethical review boards 
of the National Institute of Hygiene and Epidemiology (NIHE), Hanoi, 
Vietnam (Approved Number: IRB- VN01057), and the Institute of 
Tropical Medicine, Nagasaki University, Japan (Approved Number: 
09031837). The study was conducted in accordance with the ap-
proved guidelines.
3  | RESULTS
3.1 | Yearly incidences of paediatric ARI 
hospitalizations, LRTIs, and influenza (A/B) ARIs
During the investigation period, February 2007 through June 
2013, a total of 4429 paediatric ARI hospitalization cases were 
enrolled (Table 1), among which 496 were influenza A (single infec-
tion), and 129 were influenza B (single infection). Four cases were 
infected with both influenza A and B. Yearly incidences of paedi-
atric ARI hospitalizations, LRTIs, and overall influenza- associated 
ARI hospitalizations (both influenza A and B inclusive) were sum-
marized in Table 1. The age- stratified prevalence of influenza A 
and B among paediatric ARI hospitalizations were summarized in 
Table S1.
The incidence of influenza A and B- associated paediatric 
ARI hospitalization were highest among children younger than 
2 years (Table 1). During the first three years of the study pe-
riod (2007- 2009), the incidence of influenza B ARI hospitalization 
among children younger than two were relatively low, ranging 
from 18.2 to 164 per 100 000 population compared to influenza 
A, which was 636 to 1491 per 100 000. However, the incidence 
of influenza B ARI hospitalization among children younger than 
two increased noticeably in the post- A/H1N1pdm09 period, par-
ticularly in 2010 [255 (95% CI: 139- 427)] and 2012 [527 (95% 
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confirmed that there was statistical evidence of an increase in 
influenza B- associated paediatric ARI hospitalization in “Post- A/
H1N1pdm09” (April 2010- June 2013) when compared to “Pre- A/
H1N1pdm09” (February 2007- March 2010) [Incidence Relative 
Risk (IRR) 3.12, 95% CI: 1.01- 9.61, P = 0.047] _ENREF_17. On 
the other hand, there was no statistical evidence of an increase 
in influenza A- related ARI hospitalization incidence in post- A/
H1N1pdm09 compared to pre- A/H1N1pdm09 period [IRR 0.69, 
95% CI: 0.35- 1.38, P = 0.293].
3.2 | Demographic and clinical characteristics 
comparison between influenza B and non- influenza 
B ARIs
With regard to the demographic and clinical characterization of 
overall paediatric ARI hospitalization cases enrolled in the current 
study (n = 4,429), 2,602 were male (58.8%), and the median age (in 
months) was 16.6 (IQR: 8.6- 27.3). Other demographic information, 
including socioeconomic status, medical history, as well as detailed 
clinical information, was summarized in Table 2.
The demographic and clinical characteristics between influenza B 
(n = 133) and non- influenza B ARI groups (n = 4296) were compared 
(Table 2). The male proportion was higher in the non- influenza B 
ARI group (50.4%, influenza B vs 59.0%, non- influenza B, P = 0.046). 
Regarding the median age (in month), the influenza B ARI group was 
older (22.9, influenza B vs 16.5, non- influenza B, P < 0.001), and the 
greater proportion of ARI children were 3 years or older in the influ-
enza B ARI group. Furthermore, family smoking was more frequent 
in the influenza B ARI group (P = 0.003).
With respect to the clinical information, the respiratory rate (per 
min) was faster in the non- influenza B ARI group (32.0, influenza B vs 
33.0, non- influenza B, P = 0.012) (Table 2). Furthermore, ARI children 
with wheeze (P = 0.005) and breathing difficulty (P = 0.022) were 
more common in the non- influenza B ARI group. The proportion of 
paediatric ARI hospitalizations with chest X- ray abnormal findings 
was also greater in the non- influenza B ARI group (15.0%, influenza 
B vs 29.0%, non- influenza B, P < 0.001). The result of multivariate 
analyses presented that non- influenza B ARI cases were associated 
with the increased risks of respiratory clinical presentations after ad-
justing for sex, age, and family smoking status. For instance, the risk 
of wheeze was 1.51 (95% CI: 1.07- 2.13) times, breathing difficulty 
was 2.21 (95% CI: 1.09- 4.48) times, and chest X- ray abnormality was 
2.56 (95% CI: 1.54- 4.25) times greater in non- influenza B ARI cases. 
The median WBC titre was higher in the non- influenza B ARI group 
(9.2 × 103 cells/uL, influenza B vs 11.5 × 103 cells/uL, non- influenza 
B, P < 0.001).
Furthermore, in the comparison between influenza A and B, in-
fluenza B- associated ARI hospitalizations were slightly older with 
different age distribution pattern (P = 0.002) (Table S2). Parental 
smoking was more common in influenza B ARI group (P = 0.011). 
Regarding the clinical information, influenza A group was associated 
with higher body temperature (P = 0.003) as well as frequent pres-
ence of chest X- ray abnormality (P < 0.001).
3.3 | Yearly prevalence and seasonality of influenza 
B Victoria and Yamagata lineages
Among 133 influenza B- associated paediatric ARI hospitalization 
cases detected from February 2007- June 2013, a total of 106 influ-
enza B samples were analyzed for Haemagglutinin (HA) glycoprotein 
nucleotide sequences. Of 106 influenza B HA gene sequenced ARI 
samples, 91 (85.9%) were successfully sequenced and utilized for 
phylogenetic analysis.
Regarding the influenza B lineage- specific seasonal trend during 
the current investigation period, no distinct trend was observed in 
the pre- A/H1N1pdm09 period (Figure 1). However, starting from 
post- A/H1N1pdm09, two peaks of influenza B- associated ARIs ap-
peared within a year: from February through June and from October 
through December (Figure 1), which was mainly contributed by 
Victoria lineage- related ARI hospitalizations, particularly in 2010 
(n = 28) and 2012 (n = 37) (Table S3). On the contrary, the overall 
number of Yamagata lineage- related ARI hospitalizations was lim-
ited throughout the investigation period in both pre- and post- A/
H1N1pdm09 periods.
3.4 | Demographic and clinical characteristics 
comparison between Victoria and Yamagata lineages
In the demographic characteristics comparison between influenza B 
Victoria (n = 72) and Yamagata (n = 19) lineages, the median age (in 
month) was older among Victoria lineage ARI cases (25.8, Victoria 
lineage vs 19.7, Yamagata lineage, P = 0.056) with a slightly higher 
proportion of ARIs in the 2 years and older age group in Victoria 
lineage (P = 0.126) (Table 3). Furthermore, kindergarten attendance 
was more frequent in the Victoria lineage ARI group (55.6%, Victoria 
lineage vs 21.1%, Yamagata lineage, P = 0.010). ARI hospitalizations, 
with the presence of underlying medical conditions and co- infection 
with other respiratory viruses, were common in both lineages.
Regarding the clinical manifestation comparison between in-
fluenza B lineages, SpO2 (≦90%) was more commonly seen in the 
Yamagata lineage ARI group (15.8%, Yamagata lineage vs 1.4%, 
Victoria lineage, P = 0.028) (Table 3). Furthermore, the median body 
temperature (°C) was higher in the Yamagata lineage (38.5, Yamagata 
lineage vs 37.6, Victoria lineage, P = 0.017). Other respiratory- 
related clinical information, such as the presence of wheeze, tachy-
pnea, and chest X- ray abnormal findings were also relatively more 
common in Yamagata lineage ARI group with no statistically signifi-
cant differences.
3.5 | Seasonal prevalence of WHO Groups in 
Victoria and Yamagata lineages
The seasonal prevalence of WHO Groups in both influenza B line-
ages, circulating during the present study period, was investigated. 
With respect to the Victoria lineage, a remarkable shift in the domi-
nantly circulating WHO Group was detected in post- A/H1N1pdm09 
period: Group 5 (B/Singapore/19/2009) was the dominant type 
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TABLE  2 Demographic and clinical characteristics comparison between influenza B and non- influenza B ARI cases
Total number of paediatric ARI hospitalizations in KHGH during February 2007- June 2013 
(n = 4429)
Overall paediatric ARI 
cases (n = 4429)
Inf B positive ARI 
group (n = 133)
Non- inf B ARI group 
(n = 4296) P- valued
Total number (%)/Median (IQR)a
Demographic information
Male sex (%) 2602 (58.8%) 67 (50.4%) 2535 (59.0%) 0.046*
Median age (in month) 16.6 (IQR: 8.6- 27.3) 22.9 (IQR: 12.9- 48.7) 16.5 (IQR: 8.5- 26.9) <0.001***
Age group (%)
0- 12 month 1721 (38.9%) 34 (25.6%) 1687 (39.3%) <0.001***
13- 24 month 1435 (32.4%) 39 (29.3%) 1396 (32.5%)
25- 36 month 609 (13.8%) 12 (9.0%) 597 (13.9%)
37- 48 month 246 (5.6%) 16 (12.0%) 230 (5.4%)
49- 60 month 132 (3.0%) 10 (7.5%) 122 (2.8%)
>60 month 286 (6.5%) 22 (16.5%) 264 (6.2%)
Socioeconomic status
Daycare attendance (%) 1828 (41.3%) 61 (45.9%) 1767 (41.1%) 0.285
Family smoking (%) 2273 (51.3%) 87 (65.4%) 2186 (50.9%) 0.003**
History
Antibiotic used prior to hospitalization (%) 1699 (38.4%) 53 (39.9%) 1646 (38.3%) 0.885
Underlying medical condition (%) 1681 (38.0%) 51 (38.4%) 1630 (37.9%) 0.925
Clinical information
Vital sign(s)
Median respiratory rate (per min) 33.0 (IQR: 30.0- 40.0) 32.0 (IQR: 29.0- 37.0) 33.0 (IQR: 30.0- 40.0) 0.012*
Median body temperature (°C) 38.0 (IQR: 37.2- 38.5) 38.0 (IQR: 37.5- 38.8) 38.0 (IQR: 37.2- 38.5) 0.571
SpO2 (≦90%) 220 (5.0%) 5 (3.8%) 215 (5.0%) 0.685
Respiratory symptom and sign(s)
Wheeze (%) 2300 (51.9%) 53 (39.9%) 2247 (52.3%) 0.005**
Tachypnea (%) 889 (20.1%) 28 (21.1%) 861 (20.0%) 0.774
Breathing difficulty (%) 548 (12.4%) 8 (6.0%) 540 (12.6%) 0.022*
Crackle (%) 470 (10.6%) 20 (15.0%) 450 (10.5%) 0.092
LRTI and chest X- ray result
LRTIb(%) 1041 (23.5%) 27 (20.3%) 1014 (23.6%) 0.376
Mild LRTI (%) 676 (15.3%) 19 (14.3%) 657 (15.3%) 0.662
Severe LRTIc(%) 365 (8.2%) 8 (6.0%) 357 (8.3%) 0.421
Abnormal chest X- ray (%) 1267 (28.6%) 20 (15.0%) 1247 (29.0%) <0.001***
Radiologically- confirmed pneumonia (%) 790 (17.8%) 15 (11.3%) 775 (18.0%) 0.052
Treatment and outcome(s)
Median onset to hospitalization (in day) 2.0 (IQR: 1.0- 3.0) 2.0 (IQR: 1.0- 3.0) 2.0 (IQR: 1.0- 3.0) 0.897
Median hospitalization duration (in day) 4.0 (IQR: 3.0- 6.0) 4.0 (IQR: 2.0- 6.0) 4.0 (IQR: 3.0- 6.0) 0.037*
Antibiotic used (%) 4364 (98.5%) 132 (99.3%) 4232 (98.5%) 1.000
Steroid used (%) 2116 (47.8%) 57 (42.9%) 2059 (47.9%) 0.248
Blood WBC count (103 cells/uL) 11.4 (IQR: 8.6- 15.2) 9.2 (IQR: 7.0- 12.9) 11.5 (IQR: 8.6- 15.2) <0.001***
aIQR is an abbreviation for Interquartile Range (1st to 3rd). 
bLRTI is an abbreviation for “lower respiratory tract infection” and based on the WHO definition of clinical pneumonia24. 
cSevere LRTI was defined as the presence of a danger sign, stridor, or chest- wall indrawing. 
dProportions and median values were compared between influenza B (n = 133) and non- influenza B (n = 4296) ARI groups. All the statistically significant P- 
values are indicated in bold font. As the index for statistically significant values: * are used for P- values <0.05, ** for P- values <0.01, and *** for P- values ≦0.001.
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during Mar 2010- Mar 2011, which was rapidly replaced by Group 1 
(B/Brisbane/60/2008) in Dec 2011- Apr 2013 (Figure 2).
Regarding the seasonal prevalence of Yamagata lineage WHO 
Group, Group 2 and 3 were detected with no particular circulation 
trend or shift in dominant Group over the course of investigation 
period. A detailed seasonal prevalence of WHO Groups in both in-
fluenza B lineages was summarized in Table S3.
3.6 | Demographic and clinical characteristics 
comparison among WHO Groups of Victoria and 
Yamagata lineages
Firstly, demographic information among WHO Groups (1, 4, and 5) 
of Victoria lineage was compared (Table 4). There were no signifi-
cant differences in sex distribution and median age among the three 
groups. Daycare attendance was more common in Group 5 com-
pared to Group 1 (73.1%, Group 5 vs 45.2%, Group 1, P = 0.043). 
Furthermore, the proportion of hospitalized ARI children with an-
tibiotic usage prior to the hospital admission (P < 0.001) and the 
presence of underlying medical conditions (P = 0.002) was greater 
in Group 1 compared to Groups 4 and 5. In addition, co- infections 
with other respiratory viruses were common in both Groups 1 and 5 
(16.7%, Group 1 vs 30.8%, Group 5, P = 0.231).
With respect to clinical characterization of WHO Groups in 
Victoria lineage, wheeze (P = 0.002), tachypnea (P = 0.026), and 
crackle (P = 0.019) were more commonly observed in Group 1 than in 
the other two groups (Table 4). Furthermore, hospitalized ARI cases 
with Group 1 presented the greater proportion of LRTIs compared 
to Group 5 (23.8%, Group 1 vs 3.9%, Group 5, P = 0.041). Although 
statistically not significant, ARI children infected with Group 1 pre-
sented relatively higher proportions of chest X- ray abnormality and 
radiologically- confirmed pneumonia in comparison to Groups 4 and 5.
For demographic and clinical information comparison in 
Yamagata lineage WHO Groups, we could only include eleven ARI 
cases of Group 2 and seven of Group 3 in the statistical analyses 
(Table S4). With regard to demographic characterization, no statis-
tically significant differences were detected between Groups 2 and 
3. Both Group 2- and Group 3- associated ARI hospitalizations were 
commonly observed among children younger than 2 years. The re-
sults of a comparison in clinical manifestations did not reveal any 
significant differences.
4  | DISCUSSION
This is the first study to describe the detailed clinical- epidemiological 
information of influenza B among hospitalized paediatric ARI cases 
in Vietnam. During the study period, both influenza A and B ARI 
hospitalizations were frequently detected in children younger than 
2 years. The first A/H1N1pdm09- associated ARI hospitalization case 
was reported in July 2009.32 Noticeably, the incidence of influenza 
B ARI hospitalization in the post- A/H1N1pdm09 period increased 
dramatically, particularly in 2010 and 2012. Furthermore, Victoria 
lineage was dominant in post- A/H1N1pdm09, and the dominantly 
circulating WHO Group shifted each year. Importantly, Victoria line-
age WHO Group 1- associated ARIs were clinically more severe in 
comparison with Group 5, presenting greater proportions in wheeze, 
tachypnea, and LRTI. Therefore, our current results highlight both 
the increased clinical importance of influenza B among paediatric 
ARI hospitalizations in central Vietnam in the post- A/H1N1pdm09 
period and the difference in respiratory- related clinical severity 
among WHO Groups of Victoria lineage, which could help in the fu-
ture nationwide influenza vaccination program and for proper clini-
cal management in hospital settings.
F IGURE  1 Seasonal circulation pattern of influenza B lineages (Victoria/Yamagata) from February 2007 to June 2013. A cumulative 
number of influenza B paediatric ARI hospitalizations in each month was presented as the BLACK solid line. Victoria lineage ARI case in each 
month was shown in the BLACK box and Yamagata lineage ARI cases in the GREY box. The first A/H1N1pdm09- related ARI hospitalization 
case detected in the current study site was indicated with the down arrow. The period encompassing January 2010- June 2013 was defined 
as “Post- A/H1N1pdm09 period” and shown as a dotted- box
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During the current investigation period, overall influenza (A/B)- 
associated paediatric ARI hospitalization incidence ranged from 122 
to 267 (per 100 000 population) (Table 1). Both influenza A and B 
ARI incidences were high among children under 5 years. In fact, the 
proportion of hospitalized ARI children over 5 years was greater in 
the influenza B ARI group compared to influenza A (8.8%, influenza 
A vs 15.5%, influenza B, P = 0.002) (data not shown), which was con-
sistent with the previous reports from China and Finland.3,33,34 In the 
current study site, influenza B- related paediatric ARI hospitalization 
incidence was low in pre- A/H1N1pdm09 period. However, influ-
enza B ARI incidence dramatically increased in post- A/H1N1pdm09, 
which resembled the previous reports from Brazil, Cambodia, China, 
India, and Taiwan.4,17,18,20,21,35 As it was previously described, the 
emergence of A/H1N1pdm09 strain might have affected the viral 
etiology and seasonal circulation pattern of childhood ARIs.36 We 
concluded that the A/H1N1pdm09 outbreak occurred around mid- 
2009 in our study site and assumed that a large population in the 
community might have been infected with this new A/H1N1pdm09 
strain. This may have led to the development of non- specific antivi-
ral immunity in the target community, which may have disrupted the 
circulation trend of other respiratory viruses, including influenza B. 
Interestingly, we also observed unusual split of RSV seasonal peak in 
2010 as we previously described.37 Further studies would be neces-
sary to understand the effect of A/H1N1pdm09 on respiratory virus 
circulation trend.
Among all the paediatric ARI hospitalization cases enrolled in 
the current study, 133 were influenza B positive (Table 2). The me-
dian age in influenza B ARI group was older than non- influenza B 
ARIs, and influenza B group presented the higher proportion of fam-
ily smoking, which is known to be one of the major risk factors for 
influenza morbidity and mortality.38,39 Passive smoking from fam-
ily member might have an effect on suppression of humoral- and 
cell- mediated immunity, which makes children more susceptible to 
influenza infections. However, the mechanism is not fully under-
stood. Passive smoking in general may put children at the risk of ARI 
hospitalization due to viral infection; however, there is not yet clear 
evidence regarding the absolute effect of passive smoking on ARI 
hospitalization in different viral pathogens. The slightly older age of 
infection by influenza B compared to non- influenza B (22.9 months 
vs 16.5 months, P < 0.001) may explain an increased susceptibility 
by passive smoking in older age group. In the future study, we need 
to follow up children with positive passive smoking status in order to 
understand the effect of passive smoking on virus- related ARI hospi-
talization in each virus respectively. Regarding clinical manifestation, 
influenza B ARI group was less severe than non- influenza B, which 
might be due to the fact that influenza B ARI cases were relatively 
older. Also, the higher blood WBC titre in non- influenza B ARI group 
was most likely due to a certain proportion of bacteria- associated 
ARIs counted in non- influenza B ARI group. In the comparison be-
tween influenza A and B, there were no remarkable differences ex-
cept for the higher prevalence of parental smoking in influenza B ARI 
group (Table S2). Further study would be necessary to understand 
the effect of secondary smoking on susceptibility against influenza 
infection. In the clinical information comparison, influenza A group 
presented higher body temperature and frequent presence of chest 
X- ray abnormality. Yet, other clinical presentations were similar be-
tween two. Although a study mentioned that influenza B patients 
frequently presented gastrointestinal symptoms,40 the actual dif-
ference in clinical severity between influenza A and B has been 
controversial up to date.41-43 Further continuous epidemiological 
surveillance would be necessary to gain a deeper understanding in 
the clinical aspect of influenza infection.
With respect to influenza B lineage specific seasonal trend in our 
study site, Victoria lineage was dominant in post- A/H1N1pdm09 pe-
riod (Figure 1), which was similar to studies from India, Cambodia, 
and Taiwan.4,17,18,20 A previous report described Victoria lineage 
might possess greater viral transmissibility based on the estimated 
reproductive number (Re) as well as the faster molecular evolution-
ary rate compared to Yamagata lineage.44 The difference in viral 
transmissibility capacity between genetically distinct lineages may 
explain the predominance by Victoria lineage in the current study 
site. Furthermore, the difference in viral virulence may have played 
a role in increase of Victoria lineage- associated ARI hospitalizations. 
We also have to take the lineage- specific sero- epidemiological infor-
mation into account to gain a better understanding of influenza B lin-
eage circulation pattern. A study from Taiwan suggested switching 
of dominantly circulating lineage may occur every 2- 3 years.18 In the 
future study, we will continue monitoring the lineage- specific circu-
lation trend of influenza B strains in order to investigate the lineage- 
specific viral transmissibility based on the viral genetic variation.
Regarding the demographic information of influenza B lineages, 
median age was slightly older in Victoria lineage (Table 3), which 
contradicted the reports from China and Slovenia that presented 
Victoria lineage ARIs were younger than Yamagata lineage.21,45 The 
difference in age of infection has been controversial due to the dif-
ferences in inclusion criteria among studies. Furthermore, clinical 
aspect of influenza B lineages is poorly understood. In the current 
study, the clinical data did not present a significant difference be-
tween lineages (Table 3), which was in line with previous reports 
from China, France, Serbia, and Slovenia.41,45-48 Although the body 
temperature was slightly higher in Yamagata lineage ARIs, it was 
probably due to the difference in age distribution. In our study, the 
hospitalization duration did not differ between lineages, which con-
tradicted the previous study that presented longer time to symp-
tom resolution in Victoria lineage.47 Moreover, another study by 
Chi et al reported that Yamagata lineage ARIs were associated with 
invasive LRTI.49 Therefore, there exists inconsistency regarding the 
information of influenza B lineage- specific demographic and clinical 
characteristics.
Regarding the seasonal circulation trend of WHO Groups in 
each lineage, we did not find a distinct circulation trend in the 
pre- A/H1N1pdm09 period (Figure 2). However, starting from 
the post- A/H1N1pdm09 period, WHO Group- specific circulation 
trend became apparent in Victoria lineage, in which Group 5 was 
dominant during Mar 2010- Mar 2011, and then followed by Group 
1 in Dec 2011- Apr 2013. In HA glycoprotein coding region that we 
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TABLE  3 Demographic and clinical characteristics comparison between influenza B Victoria and Yamagata lineages
Influenza B positive paediatric ARI cases during February 2007- June 2013 (n = 133)
Influenza B Victoria lineage 
(n = 72)
Influenza B Yamagata lineage 
(n = 19)
P- valueTotal number (%)/Median (IQR)a
Demographic information
Male sex (%) 41 (56.9%) 9 (47.4%) 0.605
Median age (in month) 25.8 (IQR: 13.7- 51.5) 19.7 (IQR: 7.1- 25.2) 0.056
Age group (%)
0- 12 month 14 (19.4%) 7 (36.8%) 0.126
13- 24 month 21 (29.2%) 7 (36.8%)
25- 36 month 5 (6.9%) 2 (10.5%)
37- 48 month 12 (16.7%) 0
49- 60 month 6 (8.3%) 2 (10.5%)
>60 month 14 (19.4%) 1 (5.3%)
Socioeconomic status
Daycare attendance (%) 40 (55.6%) 4 (21.1%) 0.010*
Family smoking (%) 48 (66.7%) 12 (63.2%) 0.573
History
Antibiotic used prior to hospitalization (%) 31 (43.1%) 7 (36.8%) 0.412
Underlying medical condition (%) 26 (36.1%) 5 (26.3%) 0.588
Respiratory virus co- infection (%) 15 (20.8%) 3 (15.8%) 0.755
Clinical information
Vital sign(s)
Median respiratory rate (per min) 30.0 (IQR: 28.0- 35.0) 34.0 (IQR: 30.0- 40.0) 0.153
Median body temperature (°C) 37.6 (IQR: 37.0- 38.6) 38.5 (IQR: 37.6- 39.0) 0.017*
SpO2 (≦90%) 1 (1.4%) 3 (15.8%) 0.028*
Respiratory symptom and sign(s)
Wheeze (%) 26 (36.1%) 11 (57.9%) 0.116
Tachypnea (%) 13 (18.1%) 5 (26.3%) 0.518
Breathing difficulty (%) 5 (6.9%) 1 (5.3%) 1.000
Crackle (%) 9 (12.5%) 3 (15.8%) 0.709
LRTI and chest X- ray result
LRTIb(%) 12 (16.7%) 3 (15.8%) 1.000
Mild LRTI (%) 9 (12.5%) 2 (10.5%) 1.000
Severe LRTIc(%) 3 (4.2%) 1 (5.3%) 1.000
Abnormal chest X- ray (%) 10 (13.9%) 5 (26.3%) 0.305
Radiologically- confirmed pneumonia (%) 8 (11.1%) 3 (15.8%) 0.701
Treatment and outcome(s)
Median onset to hospitalization (in day) 2.0 (IQR: 1.0- 4.0) 1.0 (IQR: 1.0- 3.0) 0.176
Median hospitalization duration (in day) 4.0 (IQR: 2.0- 6.0) 4.0 (IQR: 2.0- 5.0) 0.507
Antibiotic used (%) 72 (100%) 18 (94.7%) 0.209
Steroid used (%) 31 (43.1%) 7 (36.8%) 0.795
Blood WBC count (103 cells/uL) 9.4 (IQR: 6.9- 13.2) 8.8 (IQR: 6.7- 12.8) 0.965
aIQR is an abbreviation for Interquartile Range (1st to 3rd). 
bLRTI is an abbreviation for “lower respiratory tract infection” and based on the WHO definition of clinical pneumonia.24 
cSevere LRTI was defined as the presence of a danger sign, stridor, or chest- wall indrawing. 
All the statistically significant P- values are indicated in bold font. As the index for statistically significant values: * are used for P-values <0.05, ** for 
P- values <0.01, and *** for P- values ≦0.001.
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targeted for nucleotide sequencing in the current study, Group 1 
and 5 possess distinct amino acid (AA) substitutions at two sites 
within major antigenic regions: 120- loop (Lysine (K) in Group 1 and 
Asparagine (N) in Group 5) and 160- loop (Lysine (K) in Group 1 and 
Asparagine (N) in Group 5)(B/Brisbane/60/2008 strain (Accession 
number: FJ766840) as the reference of AA position).50 These two 
AA substitutions were located proximity to the biding site to SA- 
galactose linkage, yet not within actual binding site. Therefore, 
genetically distinct groups may have different receptor binding 
affinities, viral transmissibility, which may have been linked with 
the sudden increase by Group 5 in Mar 2010- Mar 2011. Further 
studies would be necessary to understand the role of differences 
in AA composition within major antigenic region on the receptor 
binding capacity and viral transmissibility.
Our current result was consistent with the previous finding that a 
dominantly circulating Group in 1 year would be replaced by another 
Group in the following year.22 To the best of our knowledge, this 
was the first study describing the dramatic shift in Groups between 
years in Vietnam.
Most importantly, ARI cases infected with Victoria lineage 
Group 1 were more frequently associated with severe clinical 
manifestations such as wheeze, tachypnea, crackle and LRTI in 
comparison with Group 4 and 5. One possible explanation is the 
distinct amino acid composition within HA gene of Victoria lin-
eage Groups may possess Group- specific binding preference to 
sialic acid (SA)- galactose linkage, α2,3 or α2,6. It was previously 
described that few amino acid substitutions in HA glycoprotein 
could affect receptor binding specificity.51 For example, Asp- 225- 
Gly substitution of A/H1N1pdm09 strain resulted in increased 
binding affinity to α2,3- SA linkage, which enhanced disease se-
verity.52-54 It is important to investigate the clinical role of two 
amino acid substitutions within major antigenic regions between 
F IGURE  2 Seasonal circulation pattern of WHO Groups in Victoria lineage (top) and Yamagata lineage (bottom) from February 2007 
to June 2013. A cumulative number of influenza B lineage- specific paediatric ARI hospitalizations in each month was shown as the BLACK 
solid line. WHO Groups classification for each influenza B lineage is based on Worldwide Influenza Centre (WIC). WHO Group- specific ARI 
hospitalizations were presented as the boxes with different colors: Victoria lineage (GREY for Group 1, GREY- stripe for Group 4 and BLACK 
for Group 5) and Yamagata lineage (BLACK for Group 2 and GREY for Group 3). The period encompassing January 2010- June 2013 was 
defined as “Post- A/H1N1pdm09 period” and shown as dotted- box
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TABLE  4 Demographic and clinical characteristics comparison among WHO Groups (1, 4, and 5) in Victoria lineage
Influenza B Victoria lineage paediatric ARI cases during February 2007- June 2013 (n = 72)
WHO Group 1 (n = 42) WHO Group 5 (n = 26)
P- valueTotal number (%)/Median (IQR)a
Demographic information
Male sex (%) 23 (54.8%) 16 (61.5%) 0.622
Median age (in month) 28.1 (IQR: 13.2- 51.1) 25.0 (IQR: 17.5- 55.6) 0.601
Age group (%)
0- 12 month 10 (23.8%) 2 (7.7%) 0.223
13- 24 month 10 (23.8%) 11 (42.3%)
25- 36 month 2 (4.8%) 3 (11.5%)
37- 48 month 9 (21.4%) 3 (11.5%)
49- 60 month 4 (9.5%) 1 (3.9%)
>60 month 7 (16.7%) 6 (23.1%)
Socioeconomic status
Daycare attendance (%) 19 (45.2%) 19 (73.1%) 0.043*
Family smoking (%) 26 (61.9%) 18 (69.2%) 0.578
History
Antibiotic used prior to hospitalization (%) 23 (54.8%) 8 (30.8%) 0.004**
Underlying medical condition (%) 22 (52.4%) 4 (15.4%) 0.002**
Respiratory virus co- infection (%) 7 (16.7%) 8 (30.8%) 0.231
Clinical information
Vital sign(s)
Median respiratory rate (per min) 32.0 (IQR: 29.0- 36.0) 30.0 (IQR: 28.0- 35.0) 0.272
Median body temperature (°C) 37.6 (IQR: 37.0- 39.0) 37.5 (IQR: 37.0- 38.0) 0.148
SpO2 (≦90%) 1 (2.4%) 0 1.000
Respiratory symptom and sign(s)
Wheeze (%) 22 (52.4%) 4 (15.4%) 0.002**
Tachypnea (%) 12 (28.6%) 1 (3.9%) 0.012*
Breathing difficulty (%) 5 (11.9%) 0 0.148
Crackle (%) 9 (21.4%) 0 0.010*
LRTI and chest X- ray result
LRTIb(%) 10 (23.8%) 1 (3.9%) 0.041*
Mild LRTI (%) 7 (16.7%) 1 (3.9%) 0.131
Severe LRTIc(%) 3 (7.1%) 0 0.258
Abnormal chest X- ray (%) 7 (16.7%) 2 (7.7%) 0.298
Radiologically- confirmed pneumonia (%) 6 (14.3%) 2 (7.7%) 0.461
Treatment and outcome(s)
Median onset to hospitalization (in day) 2.0 (IQR: 1.0- 4.0) 1.5 (IQR: 0- 4.0) 0.146
Median hospitalization duration (in day) 4.0 (IQR: 2.0- 6.0) 3.5 (IQR: 2.0- 5.0) 0.171
Antibiotic used (%) 42 (100%) 26 (100%) 1.000
Steroid used (%) 16 (38.1%) 15 (57.7%) 0.115
Blood WBC count (103 cells/uL) 9.0 (IQR: 6.0- 12.4) 9.7 (IQR: 7.7- 13.4) 0.357
aIQR is an abbreviation for Interquartile Range (1st to 3rd). 
bLRTI is an abbreviation for “lower respiratory tract infection” and based on the WHO definition of clinical pneumonia.24 
cSevere LRTI was defined as the presence of a danger sign, stridor, or chest- wall indrawing. 
P- values are for proportions and median values comparison between WHO Groups 1 and 5 of Victoria lineage.
All the statistically significant P- values are indicated in bold font. As the index for statistically significant values: * are used for P- values <0.05, ** for 
P- values <0.01, and *** for P- values ≦0.001.
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Victoria lineage Group 1 and 5. Therefore, the pathological and 
clinical importance of Victoria lineage Group- specific amino acid 
composition within HA glycoprotein antigenic regions needs to be 
further investigated.
As one of the limitations in the clinical manifestation comparison 
of WHO groups, we were not capable of performing multivariate 
analysis adjusting for confounding variables due to the small sam-
ple size in each Group. Since the presence of an underlying medi-
cal condition was described to be one of the major risk factors for 
developing severe influenza B- related ARI infection,46 our primary 
clinical finding of the association of Victoria lineage Group 1 with 
clinical severity, should be carefully interpreted as its severity could 
have been effected by the higher prevalence of an underlying medi-
cal condition in Group 1. Co- infection with other respiratory viruses 
should be taken into account in future analysis as the frequency 
of co- infection with other respiratory pathogens were relatively 
high in both WHO Group 1 and 5, rate of which was comparable 
to previous studies.55,56 Some previous studies have described the 
importance of viral co- infection on clinical outcome.57,58 Bacterial 
co- infection among influenza ARIs is also known to be the risk fac-
tor for developing severe clinical manifestation.59 However, we did 
not conduct bacteria detection in the current study. Nevertheless, 
WBC count did not differ among Groups. In future studies, it 
would be important to elucidate the biological role of bacterial co- 
infection on influenza B infections. Lastly, we did not obtain clinical 
data from those who did not require hospitalization, which made it 
difficult to estimate the clinical importance of influenza B as well 
as viral transmissibility. In the future study, we would collect data 
from mild ARIs and healthy children in the target community to gain 
a better understanding of the clinical role of influenza B.
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